Skip to main page content
U.S.flag

安全状态保护

Dot gov

The.gov means it’s official。
Federal government websites often end in.gov or.mil.Beforesharing sensitive information，make sure you’re on a federalgovernment site。

Https

The site is secure。
Thehttps://ensures that you are connecting to theoffice website and that any information you provide is encryptedand transmitted securely。

存取键 NCBI Homepage 我的NCBI Homepage 主内容 主导航
。2021May；593（7857）：130-135。
doi:10.1038/s41586-021-03398-2。 Epub2021Mar8。

Antibody resistance of SARS-Cov-2variants B.1.351and B.1.1.7

Pengfei Wang # 1个单击功能区上Manoj S Nair # 1个单击功能区上竖井 # 1个单击功能区上Sho Iketani # 1个 2单击功能区上Yang Luo 1个单击功能区上Yicheng Guo 1个单击功能区上映射Wang 1个单击功能区上后宫，后宫 1个单击功能区上Baoshan Zhang 3单击功能区上Peter D Kwong 3 4个单击功能区上Barney S Graham 3单击功能区上John R Mascola 3单击功能区上Jennifer Y Chang 1个 5单击功能区上Michael T Yin 1个 5单击功能区上Magdalena Sobieszczyk 1个 5单击功能区上Christos A Kyratsous 6个单击功能区上Lawrence Shapiro 1个 4个 7单击功能区上Zizhang Sheng 1个单击功能区上阳黄 8个单击功能区上David D Ho 9 10 11
疲劳，疲劳

Antibody resistance of SARS-Cov-2variants B.1.351and B.1.1.7

Pengfei Wanget al。 自然，自然。 2021 May。

Abstract

The COVID-19pandemic has had widespread effects across the globe，and its causative agent，SARS-Cov-2，continues to spread.Effective interventions need to be developed to endthis pandemic.Single and combination therapies with monoclonal antibodies have received emergency use authorization1-3单击功能区上，自动调节装置4-7.Furthermore，多工位控制阀shown promise8个单击功能区上，including two that have an approximately95%protective efficicacy against COVID-199,10.However，these interventions were directed against the initial SARS-CoV-2virus that emerged in 2019.The recent detection of SARS-CoV-2variants B.1.1.7in the UK11and B.1.351 in South Africa12is of concern because of their purported ease of transmission and extensive mutations in the spike protein.Here we show that B.1.1.7 is refractory to neutralization by most monoclonal antibodies against the N-terminal domain of the spike protein and is relatively resistant to afew monoclonal antibodies against ains the in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in innot more resistant to plasma from individuals who have recovered from COVID-19 or sera from individuals who have been vaccinated against SARS-Cov-2.The B.1.351 variant is not only refractory to neutralization by most monoclonal antibodies against the N-terminal domain but somultiple innot against the receptor-binding motif of the receptor-binding domain，which is mostly due to a mutation causing an E484K substitution.Moreover，compared to wild-type SARS-Cov-2，B.1.351is markedly more resistant to neutralization by convalescent plasma（9.4-fold）and sera from individuals who have been vaccinated（10.3-12.4）。B.1.351 and emergent variants13,14with similar mutations in the spike protein present new challenges for monoclonal antibody therapies and threaten the protective efficacy of current vaccines。

PubMed Disclaimer

更新频率

  • Increased Resistance of SARS-COV-2 Variants B.1.351and B.1.1.7to Antibody Neutralization。
    Wang P，Liu L，Iketani S，Luo Y，Guo Y，Wang M，Yu J，Zhang B，Kwong PD，Graham BS，Mascola JR，Chang JY，Yin MT，Sobieszczyk M，Kyratsous CA，Shapiro L，Sheng Z，Nair MS，Huang Y，HoDD。 Wang P，et al。 Res Sq[Preprint]。2021 Jan29:rs.3.rs-155394。doi:10.21203/rs.3.rs-155394/v1。 Res Sq.2021。 PMID:33532763 Free PMC article。 Updated。 Preprint。
  • Antibody Resistance of SARS-COV-2 Variants B.1.351 and B.1.1.7。
    Wang P，Nair MS，Liu L，Iketani S，Luo Y，Guo Y，Wang M，Yu J，Zhang B，Kwong PD，Graham BS，Mascola JR，Chang JY，Yin MT，Sobieszczyk M，Kyratsous CA，Shapiro L，Sheng Z，Huang Y，HoDD。 Wang P，et al。 bioRxiv[Preprint]。2021Feb12:2021.01.25.428137。doi:10.1101/2021.01.25.428137。 bioRxiv.2021。 PMID:33532778 Free PMC article。 Updated。 Preprint。

Similar articles

  • Sensitivity of SARS-COV-2B.1.1.7to mRNA vaccine-elicited antibodies。
    Collier DA、De Marco A、Ferreira IATM、Meng B、Datir RP、Walls AC、Kemp SA、Bassi J、Pinto D、Silacci-Fregni C、Bianchi S、Tortorici MA、Bowen J、Culap K、Jaconi S、Cameroni E、Snell G、Pizzuto MS、Pellanda AF、Garzoni C、Riva；TIID-BiHR Reso19；mer A，Kingston N，Graves B，McCoy LE，Smith KGC，Bradley JR，Temperton N，Ceron-Gutierrez L，Barcenas-Morales G；COVID-19 Genomics UK（COG-UK）Consortium；Harvey W，Virgin HW，Lanzavecchia A，Piccoli L，Doffinger R，Wills M，Veesler D，Corti D，Gupta RK。 Collier DA，et al。 Nature.2021May；593（7857）：136-141。doi:10.1038/s41586-021-03412-7.Epub2021Mar11。 Nature.2021。 PMID:33706364
  • Escape from neutralizing antibodies by SARS-CoV-2spike protein variants。
    Weisblum Y、Schmidt F、Zhang F、DaSilva J、Poston D、Lorenzi JC、Muecksch F、Rutkowska M、Hoffmann HH、Michalidis E、Gaebler C、Agudelo M、Cho A、Wang Z、Gazumyan A、Cipolla M、Luchsinger L、Hillyer CD、Caskey M、Robbiani DF、Rice、Hanigen T，Bieniasz PD。 Weisblum Y，et al。 Elife.2020Oct28；9:e61312.doi:10.7554/eLife.61132。 Elife.2020。 PMID:33112236 Free PMC article。
  • Escape of SARS-COV-2501Y.V2from neutralization by convalescent plasma。
    Cele S，Gazy I，Jackson L，Hwa SH，Tegally H，Lustig G，Giandhari J，Pillay S，Wilkinson E，Naidoo Y，Karim F，Ganga Y，Khan K，Bernstein M，Balazs AB，Gosnell BI，Hanekom W，Moosa MS；Network for Genomic Surveillance in South Africa；COMM-IT liveira T，Sigal A。 Cele S，et al。 Nature.2021May；593（7857）：142-146。doi:10.1038/s41586-021-03471-w.Epub2021Mar29。 Nature.2021。 PMID:33780970 Free PMC article。
  • Variants of SARS-Cov-2，their effects on infection，transmission and neutralization by vaccine-induced antibodies。
    Wahid M，Jawed A，Mandal RK，Dailah HG，Janahi EM，Dhama K，Somvanshi P，Haque S。 Wahid M，et al。 Eur Rev Med Pharmacol Sci.2021 Sep；25（18）：5857-5864。doi:10.26355/eurrev_202109_26805。 Eur Rev Med Pharmacol Sci.2021。 PMID:34604978 Review。
  • Neutralising antibody escape of SARS-CoV-2spike protein:Risk assessment for antibody-based Covid-19therapeutics and vaccines。
    Focosi D，Maggi F。 Focosi D，et al。 Rev Med Virol.2021Nov；31（6）：e2231。doi:10.1002/rmv.2231.Epub2021Mar16。 Rev Med Virol.2021。 PMID:33724631 Free PMC article。 Review。
See all similar articles

Cited by

See all“Cited by”articles

参考，参考

    1. Chen，P.et al.SARS-CoV-2neutralizing antibody LY-CoV555in outpatients with COVID-19.N.Engl.J.Med.384229-237（2021）。-是的DOI-是的PubMed
    1. Hansen，J.et al.Studies in humanized mice and convalescent humans yield a SARS-Cov-2antibody cocktail.Science3691010-1014（2020）。-是的DOI-是的PubMed-是的PMC
    1. Gottlieb，R.L.et al.Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19:a randomized clinical trial.J.Am.Med.Assoc.325632-644（2021）。-是的DOI
    1. Ju，B.et al.Human neutralizing antibodies elicited by SARS-Cov-2infection.Nature584115-119（2020）。-是的DOI-是的PubMed
    1. Pinto，D.et al.Cross-neutralization of SARS-Cov-2by a human monoclonal SARS-Cov antibody.Nature583290-295（2020）。-是的DOI-是的PubMed

Publication types

SH terms

Substances

LinkOut-more resources